News

Host Jeffrey Wilken, PhD, chats with Anthony Feinstein, MPhil, PhD, FRCP, about the second day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.

Explore the latest advancements in remyelination research for multiple sclerosis, from stem cells to small molecules, and discover what’s on the horizon for therapeutic development.

A new survey presented at CMSC 2025 highlighted the prevalence of burnout and job-related stress among neurology-based advanced practice providers and clinical pharmacists in the United States.

New findings reveal ozanimod shows no significant rebound effect in relapsing MS patients after treatment discontinuation, ensuring safer transitions.

Research highlights the benefits of natalizumab during pregnancy for women with multiple sclerosis, showing reduced disease activity and improved outcomes.

The ongoing PERSEUS trial explores tolebrutinib's potential as a treatment for primary progressive multiple sclerosis, with results anticipated soon.

Host Jeffrey Wilken, PhD, chats with Marie Namey, APRN, MSCN, about the first day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.

Jeff Smith, PhD, chief executive officer at Precision Biosciences, explained the clinical potential and gene-editing mechanism of PBGENE-DMD, a one-time therapy targeting dystrophin mutations in Duchenne muscular dystrophy.

New findings reveal ocrelizumab significantly improves symptoms, cognition, and fatigue in Black and Hispanic patients with relapsing multiple sclerosis.

The vice president and franchise lead of Autoimmune at Hansa Biopharma shed insights on imlifidase’s targeted mechanism and promising phase 2 data in treating Guillain-Barré syndrome.

The vice president and franchise lead of Autoimmune at Hansa Biopharma provided clinical insights on latest phase 2 safety and efficacy data on imlifidase, an IgG-cleaving antibody, in Guillain-Barré syndrome. [WATCH TIME: 3 minutes]

The 39th CMSC Annual Meeting is set to be held May 28-31, 2025, in Phoenix, Arizona. The International Journal of MS Care has published the abstracts.

Nuvig's NVG-2089 shows promise in CIDP treatment, offering a safer, more efficient alternative to IVIg with a patient-friendly trial design.

In this episode, a duo of neurologists examine the plausibility, limitations, and risks of holistic approaches to remyelination—and what patients should prioritize or avoid.

Panelists Ari Green, MD, and Paul Tesar, PhD, explore the scientific rationale and clinical complexity behind promising remyelination agents currently in development for multiple sclerosis.

BioVie initiates a phase 2 trial for bezisterim, targeting neurological symptoms of Long COVID, aiming to improve patient quality of life.

Here's some of what is coming soon to NeurologyLive® this week.

Episode 4 covers how aging and disease duration impact remyelination potential and the strategies for targeting repair across the multiple sclerosis spectrum.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on headache/migraine presenting to the ER.

Investigators explore a phase 4 trial transitioning CIDP patients from IVIg to efgartigimod, aiming to enhance treatment safety and efficacy.

In this episode, panelists outline the key scientific and clinical challenges in translating remyelination research into effective therapies for patients with MS.

Neurology News Network. for the week ending May 24, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 23, 2025.

Neurologists Ari Green, MD, and Paul Tesar, PhD, discuss the current limitations of remyelination assessment tools in MS and highlight efforts to develop more reliable clinical measures.

A recent study suggests rituximab may benefit CIDP patients, showing improvement in neurofilament levels and clinical outcomes after treatment.

The assistant professor of neurology at Robert Wood Johnson Medical School talked about a collaborative initiative that aims to address AD disparities in Asian and Pacific Islander American populations. [WATCH TIME: 3 minutes]

Researchers reported that both EN001 and insulin improved muscle strength and nerve function in models of Charcot-Marie-Tooth disease type 1A, with combined treatment showing enhanced effects.

Newly presented findings from the NEURO-TTRansform study identified thresholds for meaningful improvement in symptoms and disability, which were exceeded by eplontersen treatment.